Drug therapy in headache

Author: Mark W Weatherall

Drug therapy in headache

All physicians will encounter patients with headaches. Primary headache disorders are common, and often disabling. This paper reviews the principles of drug therapy in headache in adults, focusing on the three commonest disorders presenting in both primary and secondary care: tension-type headache, migraine and cluster headache. The clinical evidence on the basis of which choices can be made between the currently available drug therapies for acute and preventive treatment of these disorders is presented, and information given on the options available for the emergency parenteral treatment of refractory migraine attacks and cluster headache.

KEYWORDS: Migraine, tension-type headache, cluster headache, analgesics, triptans, CGRP, prophylaxis

Introduction

Headache is the most common neurological problem encountered by physicians: it accounts for 4.4% of all consultations in general practice, approximately 5% of all medical admissions to hospital, and approximately 20% of neurology outpatient consultations. While tension-type headache (TTH) is the commonest of the primary headache disorders, with a lifetime prevalence of >90%, it is rarely disabling. Migraine, which affects over 20% of people at some point in their lives, is typically so debilitating that the World Health Organisation (WHO) equates the disability caused by a day of severe migraine to quadriplegia. Migraine is so common that, even though for many people it is no more than an inconvenience, the cumulative burden of the disorder caused it to rank in the top 40 conditions causing worldwide disability according to the WHO 2012 global burden of disease figures, above all other neurological disorders other than stroke, meningitis and epilepsy; in the UK it ranks third behind stroke and the dementias, causing the loss of 230,000 disability-adjusted life years annually. Some of the rarer primary headache disorders, such as cluster headache, paroxysmal hemicrania and short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) syndrome, are among the most painful conditions known, and impose substantial disability on those unfortunate enough to suffer from them. This paper outlines the options available for drug therapy in adults in the three commonest primary headache disorders: TTH, migraine and cluster headache.

Principles of drug therapy in headache

Drug therapy is only part of an effective approach to the management of headaches. In many cases headache triggers can be identified and lifestyle changes instituted that reduce the frequency of attacks. Rest, sleep and adequate hydration are often important components of successful management regimes. Many headaches, particularly TTHs, will settle spontaneously without the need to therapy. However, if this is not the case, drug therapy is the mainstay of headache management and there are a number of principles that guide the choice and deployment of effective medication.

First and foremost it is important to make the correct diagnosis. The International Classification of Headache Disorders (ICHD) comprises a large number of primary and secondary headache disorders, but in everyday practice the commonest conditions that will present to physicians are migraine, TTH and cluster headache. This review will concentrate on the treatment of these three conditions. The ICHD criteria for these three conditions are given in Box 1; it is important to remember that not everyone’s headache has ‘read the textbook’, and that it is permissible and necessary to make a working diagnosis even if the history does not include all the features that can be seen in any given condition.

Establishing a diagnosis then allows the appropriate drugs to be chosen. While some acute and preventive medications have a broad spectrum of effect over a number of conditions, others are specific to particular types of headache. These drugs must be given at effective doses, using the most appropriate route of delivery for the patient. Acute treatments should be given early when the pain is mild, with consideration given to using combinations of drugs to treat pain and other associated symptoms such as nausea. Patient comorbidity and prior experience will guide treatment choices in some cases. Finally, when considering acute treatment, it is important to avoid drugs with high potential for medication overuse headache, and advise patients on appropriate limits with regard to frequency of administration.

Preventive treatment aims to reduce the frequency, severity and duration of headaches, and avoid medication-overuse headache. There are no hard and fast rules on when preventive treatment should be offered, but typically one would discuss this with patients when there are attacks causing frequent...
Box 1. ICHD-3 definitions: TTH, migraine (without aura) and cluster headache.

**Infrequent TTH**

A. At least 10 episodes of headache occurring on <1 day/month (<12 days/year) and fulfilling criteria B–D.
B. Lasting from 30 minutes to 7 days.
C. ≥ 2 of the following four characteristics:
   > bilateral location
   > pressing or tightening (non-pulsating) quality
   > mild or moderate intensity
   > not aggravated by routine physical activity.
D. Both of the following:
   > no nausea or vomiting
   > no more than one of photophobia or phonophobia.
E. Not better accounted for by another ICHD-3 diagnosis.

**Migraine without aura**

A. At least five attacks fulfilling criteria B–D.
B. Headache attacks lasting 4–72 hours (untreated or unsuccessfully treated).
C. Headache has ≥2 of the following characteristics:
   > unilateral location
   > pulsating quality
   > moderate or severe pain intensity
   > aggravation by or causing avoidance of routine physical activity (eg walking, climbing stairs).
D. During headache ≥ 1 of the following:
   > nausea and/or vomiting
   > photo- and phonophobia.
E. Not better accounted for by another ICHD-3 diagnosis.

**Cluster headache**

A. At least five attacks fulfilling criteria B–D.
B. Severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 15–180 minutes (when untreated).
C. Either or both of the following:
   > ≥ 1 of the following ipsilateral symptoms or signs:
     > conjunctival injection and/or lacrimation
     > nasal congestion and/or rhinorrhea
     > eyelid oedema
     > forehead and facial sweating
     > forehead and facial flushing
     > sensation of fullness in the ear
     > miosis and/or ptosis
   > a sense of restlessness or agitation.
D. Frequency from 1/2 day to 8/day for more than half the time when active.
E. Not better accounted for by another ICHD-3 diagnosis.

ICHDI-3 = International Classification of Headache Disorders 3; TTH = tension-type headache.

disability (eg ≥2 attacks/month that produce disability lasting for 3 days or more), where acute treatments are either contraindicated or ineffective, or where the headache phenotype is unusual, such as hemiplegic migraine, migraine with prolonged aura or cluster headache. Before prescribing, the benefits (reduction in attacks) and risks (adverse effects) of treatment should be discussed, and patients reminded that acute treatment will still be required.

**Tension-type headache**

TTH is by definition mild or moderate at worst, and often needs no specific therapy unless attacks are intrusive or particularly frequent. Guidelines for the treatment of TTH have been published by the British Association for the Study of Headache (BASH) and the European Federation of Neurological Societies (EFNS). Protocols have recently been published in the Cochrane library for forthcoming reviews of several acute and preventive treatments for TTH.

**Acute treatment of TTH**

Paracetamol 1,000 mg, aspirin 500–1,000 mg and several non-steroidal anti-inflammatories (NSAIDs), including ibuprofen 200–800 mg, ketoprofen 25 mg and naproxen 250–500 mg, have been shown to be effective in the acute treatment of TTH. Paracetamol has not been shown to be effective at doses below 1,000 mg and some studies have shown it to be less effective than NSAIDs. Combination analgesics containing caffeine may be more effective still, but are likely to carry a greater propensity to induce medication overuse headache – though it is unlikely that patients with TTH alone, without a personal or family history of migraine, are susceptible to this condition.

**Preventive treatment of TTH**

There are few good-quality trials of preventive treatment of TTH. The best evidence exists for amitriptyline 75 mg daily, the first reports of this dating back over 50 years. This medication is best commenced at 10–25 mg daily, and titrated steadily upwards until a positive response is achieved or intolerable side effects (typically drowsiness, dry eyes, dry mouth or constipation) are experienced. Mirtazapine 30 mg daily and venlafaxine 150 mg daily, modern antidepressants that affect both serotonin and noradrenaline metabolism, have also been shown to be effective in reducing migraine pain, and other drugs are available that block the physiological processes underlying aura (cortical spreading depression), but a series of analgesics requires acute treatment. There are no acute treatments currently available that block the physiological processes underlying aura (cortical spreading depression), but a series of analgesics have been shown to reduce migraine pain, and other drugs are available to treat the aura that is commonly found in migraine attacks. The National Institute for Health and Care Excellence (NICE) have recently published guidance on the diagnosis and treatment of migraine, and further consensus guidelines have been published by BASH, the American Headache Association (AHA) and the European Headache Federation (EHF).
Acute treatment of migraine

Several Cochrane systematic reviews exist of evidence base for commonly used acute treatments for migraine. Of the commonly available over-the-counter drug therapies, paracetamol 1,000 mg is superior to placebo (number needed to treat (NNT) 12 for two-hour pain freedom), its effectiveness being significantly increased by the addition of metoclopramide 10 mg.20 Aspirin 900–1,000 mg is more effective than being significantly increased by the addition of metoclopramide 10 mg.20 Aspirin 900–1,000 mg is more effective than ibuprofen 400 mg (NNT 7.2), while naproxen 500–825 mg is not (NNT 11).21–24 There is no consensus on which antiemetic is most helpful for migraine-associated nausea and vomiting; in addition to metoclopramide, domperidone 10 mg (higher doses now being regarded as inadvisable because of the risk of QT prolongation), buccal prochlorperazine or cyclizine may be considered. If nausea cannot be controlled, then analgesics taken per rectum can be helpful.

If simple analgesics do not control migraines adequately, patients are often prescribed or procure combination analgesics containing paracetamol and codeine. There are very few trials of opiate medication in migraine; one study indicates that a combination of codeine 25 mg and paracetamol 1,000 mg is no better than aspirin.25 Given the known risks of rapid habituation to opiates, and of developing rebound headache and medication overuse, the use of opiates for migraine should be a last resort when all other acute treatments are either ineffective or contraindicated.

Therefore if simple analgesics are ineffective, patients should be offered triptans. Triptans are 5-hydroxytryptamine (5HT) agonists, believed to exert their effect through modulation of the release of calcitonin gene-related peptide (CGRP) both peripherally and centrally. There are seven different triptans currently available in a number of formulations giving various options for route of delivery, including oral tablets or melts, nasal sprays and subcutaneous injection. Inhaled and transdermal formulations are under development. All the seven currently available triptans – sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan – have been shown to be effective in the acute treatment of migraine, with NNTs between 2.3 and 11.3. Table 1 presents the most recent meta-analyses for each formulation,26–29 and Fig 1 summarises the relative efficacy of simple analgesics and the triptans.

If first choice triptan therapy proves ineffective despite being taken early in the attack (that is, as soon as the pain starts), then one should consider increasing the dose, altering the mode of delivery or trying another member of the class. If headache recurrence is a problem, then one can consider using naratriptan or frovatriptan, which have longer half-lives than the other triptans, or using a combination of a triptan and long-acting NSAID such as naproxen.

Triptans are generally very safe and well tolerated. The commonest side effects are nausea, and tight or burning sensations in the head, neck or chest; the latter can be disconcerting but are not associated with either myocardial ischaemia or muscle breakdown. Serious cardiovascular adverse effects are very rare, occurring in less than one in one million exposures.32 Nonetheless, triptans are contraindicated in patients with uncontrolled hypertension, previous myocardial infarction, TIA or stroke, and peripheral vascular disease.

While not generally recommended for use in pregnancy or breast feeding, both a population-based epidemiological study and a long-term cohort study have concluded that there is no evidence that triptan use causes any increase in the rates of significant foetal abnormality.33,34

Table 1. NNTs for pain freedom at two hours with triptans in acute migraine.

<table>
<thead>
<tr>
<th>Reference(s)</th>
<th>Triptan</th>
<th>NNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cochrane reviews:</td>
<td>SUM 25</td>
<td>6.2 (4.9–8.5)</td>
</tr>
<tr>
<td>Lance and Curran15</td>
<td>SUM 50</td>
<td>6.1 (5.5–6.9)</td>
</tr>
<tr>
<td>Bendtsen et al16</td>
<td>SUM 100</td>
<td>4.7 (4.3–5.1)</td>
</tr>
<tr>
<td>Bendtsen and Jensen17</td>
<td>SUM sc</td>
<td>2.3 (2.1–2.4)</td>
</tr>
<tr>
<td></td>
<td>SUM + NAP</td>
<td>4.9 (4.3–5.7)</td>
</tr>
<tr>
<td></td>
<td>SUM NS 10</td>
<td>7.3 (5.5–11)</td>
</tr>
<tr>
<td></td>
<td>SUM NS 20</td>
<td>4.7 (4.0–5.9)</td>
</tr>
<tr>
<td></td>
<td>ZOM 2.5</td>
<td>5.1 (4.7–5.7)</td>
</tr>
<tr>
<td></td>
<td>ZOM 5</td>
<td>4.5 (4.2–4.9)</td>
</tr>
<tr>
<td></td>
<td>ZOM 10</td>
<td>3.1 (2.7–3.7)</td>
</tr>
<tr>
<td>Zissis et al18</td>
<td>ALMO 12.5</td>
<td>5.2 (3.5–7.0)</td>
</tr>
<tr>
<td>Loder et al19</td>
<td>RIZ 10</td>
<td>3.2 (2.9–3.5)</td>
</tr>
<tr>
<td></td>
<td>NAR 2.5</td>
<td>8.2 (5.0–21.4)</td>
</tr>
<tr>
<td></td>
<td>FROVA 2.5</td>
<td>11.3 (9.3–14.3)</td>
</tr>
<tr>
<td>Derry and Moore20</td>
<td>ELE 80</td>
<td>3.7 (3.4–4.2)</td>
</tr>
<tr>
<td></td>
<td>ELE 40</td>
<td>4.5 (3.9–5.1)</td>
</tr>
</tbody>
</table>

| Drug therapy in headache | |

While not generally recommended for use in pregnancy or breast feeding, both a population-based epidemiological study and a long-term cohort study have concluded that there is no evidence that triptan use causes any increase in the rates of significant foetal abnormality.33,34

Refractory migraine

When standard acute therapies fail, patients may present to physicians in ‘status migrainosus’, that is, with a persistent migraine refractory to treatment, requiring parenteral therapy. A number of options exist in addition to subcutaneous sumatriptan, already discussed. A recent systematic review by the Canadian Headache Society strongly recommended the use of prochlorperazine (10 mg iv), lysine acetylsalicylic acid (1.0–1.8 g iv), metoclopramide (10–20 mg iv) or ketorolac (60 mg im or 30 mg iv).35 Weaker evidence exists for the use of chlorpromazine (25 mg iv) and dihydroergotamine (1 mg im or sc). If migraine persists despite the options outlined above, repetitive infusions of intravenous dihydroergotamine at 1 mg tds up to a total of 10 mg can be effective.36

Preventive treatment of migraine

The first randomised controlled trial of a preventive treatment for migraine (methysergide) was published in 1964. Over the succeeding five decades, numerous further trials have appeared: guidance on the choices available for the preventive treatment of migraine can be found in the 2012 NICE guidelines (currently under revision), and in the consensus statements of BASH, the AHA and the EHF.

© Royal College of Physicians 2015. All rights reserved.
a responder rate of 55% versus 34% with placebo.38 Since controlled randomised trial of amitriptyline 25 mg showed in the late 1960s; in 1979 a small double-blinded placebo-controlled trial over 12 weeks to reduce the mean number of headache days from 18.5 with placebo to 13.6 with candesartan, 16 mg was shown in a small double-blind placebo-controlled crossover trial over 12 weeks to reduce the mean number of headache days from 18.5 with placebo to 13.6 with candesartan, with a 50% responder rate of 53% compared with 31% with placebo.14 Common side effects include fatigue (often in the form of decreased exercise tolerance), dizziness, insomnia, depression and decreased libido; where CNS side effects are prominent, atenolol can be helpful as it has lower CNS penetrance than the other effective β-blockers. β-blockers with partial agonist properties do not. While NICE has recommended topiramate as a first-line migraine preventive, many physicians regard its side effect profile as a deterrent to its use at that stage. Many headache specialists will use either a β-blocker or a tricyclic antidepressant in the first instance, depending on patient preference and comorbidity. Pure β-blockers, such as propranolol, nadolol, metoprolol, atenolol, timolol and bisoprolol, have proven efficacy in migraine prophylaxis, whereas β-blockers with partial agonist properties do not. Trials comparing one β-blocker against another generally show equivalent effect with equipotent doses, with overall responder rates (that is, the percentage of patients experiencing a 50% reduction in headache days) being 53% compared with 31% with placebo.15 Common side effects include fatigue (often in the form of decreased exercise tolerance), dizziness, insomnia, depression and decreased libido; where CNS side effects are prominent, atenolol can be helpful as it has lower CNS penetrance than the other effective β-blockers. β-blockers are contraindicated in patients with asthma, COPD, Raynaud’s and peripheral vascular disease.

Amitriptyline was first reported to be helpful for migraine in the late 1960s; in 1979 a small double-blinded placebo-controlled randomised trial of amitriptyline 25 mg showed a responder rate of 55% versus 34% with placebo.16 Since then a number of comparative trials have demonstrated the non-inferiority of amitriptyline to other standard preventives, including propranolol and topiramate.17,18 Side effects, such as fatigue, dry eyes, dry mouth or constipation, are common; anecdotally, other tricyclics, such as nortriptyline or dosulepin, may be better tolerated.

While several anticonvulsants have been shown to be effective for migraine prophylaxis, good-quality evidence only exists for topiramate and sodium valproate.41 Negative trials exist for lamotrigine, oxcarbazepine and vigabatrin, and only very poor-quality studies exist for carbamazepine and clonazepam. Initial trials suggesting a role for gabapentin in migraine prophylaxis have been largely discredited and the evidence now suggests that this medication is ineffective.42 Only small open trials exist for pregabalin and tiagabine; positive but small randomised controlled trials and non-inferiority trials indicate that zonisamide and levetiracetam might be worthy of further study. Topiramate was studied in a series of landmark trials that showed significant responder rates of approximately 50% versus 23% with placebo at 100 mg daily, and non-inferiority to propranolol.43 Adverse effects are common and often limiting; these include paresthesia, fatigue, tremor, weight loss, visual disturbances (including acute glaucoma), kidney stones and cognitive problems, such as word-finding difficulties, agitation, confusion, depression or psychosis. Trials of sodium valproate as a preventive treatment for migraine date back to the early 1990s. Pooled results from several trials show a responder rate of 50% versus 18% with placebo.44 Sodium valproate may cause fatigue, nausea, tremor, weight gain, hair loss, thrombocytopenia, and liver or pancreatic dysfunction. It must also be used with extreme caution in women of child-bearing age as increasing evidence links the use of valproate in pregnancy with adverse neurodevelopmental outcomes in the child.45 There are a few other oral migraine preventive therapies with some supportive evidence from clinical trials. Candesartan 16 mg was shown in a small double-blind placebo-controlled crossover trial over 12 weeks to reduce the mean number of headache days from 18.5 with placebo to 13.6 with candesartan, with a 50% responder rate of 40.4%.46 In a 2013 trial by the same Norwegian group, candesartan was non-inferior to propranolol, the proportion of responders being significantly higher with candesartan (43%) and propranolol (40%) than placebo (23%).47 The calcium channel blocker flunarizine is widely used in Europe and South America as a first-line prophylactic medication, and is regarded by many as the drug of choice for severe aura, hemiplegic migraine and migraineous vertigo. One well-conducted trial shows it to be as effective as propranolol.48 It is available in the UK on a ‘named patient’
basis. Riboflavin (vitamin B2) showed a responder rate of 56% versus 19% on placebo in one small trial, though the baseline attack frequency was very low.49

The most recent addition to the options available for the preventive treatment of migraine is Botox (onabotulinum toxin A). Reports of the potential usefulness of this therapy for migraine date back to the mid 1990s, but Botox has only been shown to be unequivocally effective in patients with chronic migraine, that is, headaches on ≥15 days/month, of which at least 8 are migraine or treated as such. Two large high-quality trials (the PREEMPT study) demonstrate a statistically and clinically significant benefit of Botox over placebo.50 On this basis, Botox was licensed for chronic migraine and ultimately approved by NICE for use in the NHS in patients unresponsive to ≥3 previous preventive treatments in whom medication overuse headache has been addressed.

Cluster headache

Cluster headache inevitably requires drug therapy. Approximately 80% of cluster headache sufferers have the episodic form of the disorder in which attacks come in bouts lasting days to weeks, with significant periods of remission in between. These patients require acute treatments, as well as transitional treatments to try to abort or shorten the bout. The remaining 20% of sufferers have the chronic form of the disorder, in which acute treatments need to be supplemented with preventive therapy. Useful guidelines for treatment have been published by the EFNS.51

Acute and transitional treatments for cluster headache

Only two acute treatments have been shown to be effective for cluster headaches: triptans and high-flow oxygen. Because of the rapid onset and severity of cluster pain, oral triptans are not effective. Subcutaneous sumatriptan 6 mg has been shown to render 48% of patients pain free at 15 minutes versus 17% placebo (NNT 3.3), whereas intranasal zolmitriptan 10 mg only rendered 12% pain free versus 3% placebo (NNT 11).52 Intranasal sumatriptan 20 mg was shown in one trial to render 57% patients pain free at 30 minutes versus 26% placebo.53 High-flow 100% oxygen (12 l/min delivered by face mask) has been shown to render 78% pain free at 15 minutes versus 20% placebo.54 For most patients, a combination of a non-oral triptan and oxygen will be effective; unlike patients with migraine, cluster headache sufferers do not seem to run into problems with medication overuse headache unless they have a personal or strong family history of migraine.55

The use of oral steroids to settle a bout of cluster headache dates back to the 1970s. The original observation, that prednisolone at doses ≥240 mg daily can reduce or abolish cluster pain in a significant proportion of sufferers, but that recurrence is common (up to 80%) as the dose is tailed off, remains true.56 Steroids therefore help by aborting the bout in a small proportion of sufferers, providing respite and the chance to introduce another preventive treatment in others.

Preventive treatment for cluster headache

The usual first-line preventive treatment for cluster headache is verapamil. This has been shown to be effective at a dose of 360 mg daily,57 though in some cases patients may benefit from titration of the dose as high as 960 mg daily. Patients may experience dizziness, fatigue and constipation on this medication, and the ECG should be checked regularly (even when established on a stable dose) to look for the development of a prolonged PR interval and ultimately heart block.58

If verapamil is not tolerated or effective, then typical second-line therapies include topiramate and lithium carbonate. Only open-label studies exist for the former, and while one crossover study suggested that the latter was as effective as verapamil,59 a subsequent placebo-controlled randomised controlled trial of lithium carbonate (modified release) 800 mg daily did not demonstrate superiority over placebo.60 Similarly, the positive results seen in open studies of sodium valproate could not be replicated in a controlled trial.61 There is one trial that shows that melatonin 10 mg can be effective for the prevention of cluster headache.62 Further studies are urgently required in this area.

Conclusion

Numerous options exist for both acute and preventive drug therapy in TTH, migraine and cluster headache. By choosing options backed by good-quality clinical trial evidence, and using them according to the principles outlined in the first section of this paper, it is possible to make a significant difference to the lives of the vast majority of patients with these primary headache disorders. For those who remain refractory to currently available treatments, the approach of a new generation of drugs targeted at CGRP, the lynchpin molecule of both migraine and cluster headache, holds out hope of improvement in the not-too-distant future.63

References


© Royal College of Physicians 2015. All rights reserved.


30 Adelman J, Belsey J. Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. J Managed Care Pharm 2003;9:45–52.


Address for correspondence: Dr M Weatherall, Princess Margaret Migraine Clinic, Department of Neurology, Charing Cross Hospital, Fulham Palace Road, London, W6 8RF, UK.
Email: mweatherall@nhs.net

Delivering the Future Hospital Medicine 2015:
RCP annual conference

The RCP is proud to announce that the abstracts presented at the Medicine 2015 annual conference are now available online. This year’s flagship conference focused on the Future Hospital Commission’s vision to structure hospital services around the needs of patients, as well as implement real change across hospitals and the wider health and social care economy.

All of the abstracts published in both Clinical Medicine and Future Hospital Journal are available for free at:
http://www.clinmed.rcpjournal.org/